MST1 knockdown inhibits osteoarthritis progression through Parkin‐mediated mitophagy and Nrf2/ NF ‐ κB signalling pathway
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.18476 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Hantao Ye und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China. Hauptthemen laut MEDLINE: Apoptosis, Chondrocytes, Disease Progression, Mitophagy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Province Natural Science Foundation, the Science and Technology Plan Project of Wenzhou, Science and Technology Plan Project of Wenzhou Municipality.
Abstract (Originalsprache)
Osteoarthritis (OA) is a complicated disease that involves apoptosis and mitophagy. MST1 is a pro‐apoptotic factor. Hence, decreasing its expression plays an anti‐apoptotic effect. This study aims to investigate the protective effect of MST1 inhibition on OA and the underlying processes. Immunofluorescence (IF) was used to detect MST1 expression in cartilage tissue. Western Blot, ELISA and IF were used to analyse the expression of inflammation, extracellular matrix (ECM) degradation, apoptosis and mitophagy‐associated proteins. MST1 expression in chondrocytes was inhibited using siRNA and shRNA in vitro and in vivo. Haematoxylin–Eosin, Safranin O‐Fast Green and alcian blue staining were used to evaluate the therapeutic effect of inhibiting MST1. This study discovered that the expression of MST1 was higher in OA patients. Inhibition of MST1 reduced inflammation, ECM degradation and apoptosis and enhanced mitophagy in vitro. MST1 inhibition slows OA progression in vivo. Inhibiting MST1 suppressed apoptosis, inflammation and ECM degradation via promoting Parkin‐mediated mitophagy and the Nrf2‐NF‐κB axis. The results suggest that MST1 is a possible therapeutic target for the treatment of osteoarthritis as its inhibition delays the progression of OA through the Nrf2‐NF‐κB axis and mitophagy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.
- Key Laboratory of Orthopaedics of Zhejiang Province, Wenzhou, China.
- The Second School of Medicine, Wenzhou Medical University, Wenzhou, China.
- The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
ORCID-Profile: Xiaolong Shui
Förderung
- Zhejiang Province Natural Science Foundation
- the Science and Technology Plan Project of Wenzhou
- Science and Technology Plan Project of Wenzhou Municipality
Zitieren
APA
Ye, H., Cai, T., Shen, Y., Zhao, L., Zhang, H., Yang, J., Li, F., Chen, J., & Shui, X. (2024). MST1 knockdown inhibits osteoarthritis progression through Parkin‐mediated mitophagy and Nrf2/ NF ‐ κB signalling pathway. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18476
Vancouver
Ye H, Cai T, Shen Y, Zhao L, Zhang H, Yang J, et al. MST1 knockdown inhibits osteoarthritis progression through Parkin‐mediated mitophagy and Nrf2/ NF ‐ κB signalling pathway. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18476
BibTeX
@article{Ye2024,
author = {Ye, Hantao and Cai, Tingwen and Shen, Yang and Zhao, Lin and Zhang, Haojie and Yang, Jianxin and Li, Feida and Chen, Jiaoxiang and Shui, Xiaolong},
title = {MST1 knockdown inhibits osteoarthritis progression through Parkin‐mediated mitophagy and Nrf2/ NF ‐ κB signalling pathway},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.18476}
}
EUVIMED